Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa

This article was originally published in The Pink Sheet Daily

Executive Summary

With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
Advertisement

Related Content

Xarelto Label Expansion Plans Slowed By FDA “Complete Response” On ACS Claim
Xarelto Label Expansion Plans Slowed By FDA “Complete Response” On ACS Claim
ATLAS Data Not Strong Enough To Support Xarelto’s Use In ACS, FDA Panel Says
Xarelto's Efficacy Impresses In ACS, But Bleeding Risk Will Complicate Approval
ROCKET AF’s Design Causes Headaches For Xarelto Sponsors
Bayer/J&J's Xarelto Gets Advisory Cmte. Endorsement In A-Fib, But Not First-Line Use
Xarelto's Comparative Efficacy To Warfarin, Pradaxa Will Be Focus At FDA Panel Review
Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?
Xarelto Approval For DVT Bodes Well For Coming Indications
Xarelto Approval For DVT Bodes Well For Coming Indications

Topics

Advertisement
UsernamePublicRestriction

Register

PS073011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel